Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 12/20 | 0.38 |
| ▸ | LMNA | P02545 | 6/20 | 0.38 |
| ▸ | TP53 | P04637 | 5/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23498365 | 1.00 | TRPM8 (0.38) | TRPM8LMNATP53GBA1POLB | |
| SCHEMBL23498478 | 0.90 | LMNA (0.37) | TRPM8LMNATP53GBA1POLB | |
| SCHEMBL23498895 | 0.88 | GBA1 (0.35) | TRPM8LMNATP53GBA1POLB | |
| SCHEMBL29998001 | 0.88 | GBA1 (0.35) | TRPM8LMNATP53GBA1POLB | |
| SCHEMBL23498448 | 0.85 | TSHR (0.38) | LMNATP53POLBMAPTTHRB | |
| SCHEMBL29997987 | 0.85 | TSHR (0.38) | LMNATP53POLBMAPTTHRB | |
| SCHEMBL23499142 | 0.85 | THRB (0.39) | TRPM8LMNATP53POLBTHRB | |
| SCHEMBL22357257 | 0.84 | TP53 (0.38) | TRPM8LMNATP53GBA1POLB | |
| SCHEMBL23518801 | 0.84 | GBA1 (0.35) | TRPM8LMNATP53GBA1POLB | |
| SCHEMBL30980438 | 0.81 | TP53 (0.37) | TRPM8LMNATP53POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230057568-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| EP-4072677-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC Therapeutics, Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230057568-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | SNRPB2, SYNCRIP, HNRNPUL2 | TRPM8 2690/4885LMNA 292/4885TP53 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.